Health Canada has indicated that it will open access to restricted medicines including psilocybin and MDMA for appropriate patients through its Special Access Program. As these medicines become available to patients, the Centre's faculty will begin offering treatment, which will include:

  • MDMA-assisted psychotherapy for Posttraumatic Stress Disorder (PTSD), in collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS)
  • Psilocybin-assisted psychotherapy for end-of-life distress
  • Psilocybin-assisted psychotherapy for treatment-resistant depression

The Centre's faculty will also begin collecting safety and quality improvement data to inform future clinical programming. An early priority will be to treat vulnerable populations who are historically underrepresented in clinical trials, including refugees, members from BIPOC and LGBTQ+ communities and individuals from low socioeconomic backgrounds. The Centre will also recruit therapists from these communities for training through its Certificate program.

To make a donation to support the Nikean Psychedelic Psychotherapy Research Centre or for more information about the Centre for Mental Health's fundraising priorities, please visit UHN Foundation.